{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:50:56Z","timestamp":1776819056099,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-024-01336-4","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:27:55Z","timestamp":1737026875000},"page":"307-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials"],"prefix":"10.1007","volume":"15","author":[{"given":"Markus V.","family":"Heppt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kilian","family":"Trin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-C\u00e9cile","family":"Mille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Groc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6854-9996","authenticated-orcid":false,"given":"Nathalie","family":"B\u00e9geault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","volume":"23","author":"L Del Regno","year":"2022","unstructured":"Del Regno L, Catapano S, Di Stefani A, Cappilli S, Peris K. A review of existing therapies for actinic keratosis: current status and future directions. Am J Clin Dermatol. 2022;23:339\u201352.","journal-title":"Am J Clin Dermatol"},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","volume":"28","author":"T Dirschka","year":"2017","unstructured":"Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28:431\u201342.","journal-title":"J Dermatolog Treat"},{"key":"1336_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/jcm11061654","volume":"11","author":"MV Heppt","year":"2022","unstructured":"Heppt MV, Dykukha I, Graziadio S, Salido-Vallejo R, Chapman-Rounds M, Edwards M. Comparative efficacy and safety of tirbanibulin for actinic keratosis of the face and scalp in Europe: a systematic review and network meta-analysis of randomized controlled trials. J Clin Med. 2022;11:1654.","journal-title":"J Clin Med"},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/phpp.12870","volume":"39","author":"G Pellacani","year":"2023","unstructured":"Pellacani G, Peris K, Ciardo S, et al. The combination of oral and topical photoprotection with a standardized Polypodium leucotomos extract is beneficial against actinic keratosis. Photodermatol Photoimmunol Photomed. 2023;39:384\u201391.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1336_CR5","first-page":"1218","volume":"15","author":"MA Dohil","year":"2016","unstructured":"Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol. 2016;15:1218\u201324.","journal-title":"J Drugs Dermatol"},{"key":"1336_CR6","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","volume":"85","author":"DB Eisen","year":"2021","unstructured":"Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85:e209\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"1336_CR7","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3690","volume":"101","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Painchault C, Brignone M. Systematic literature review and network meta-analysis of the efficacy and acceptability of interventions in actinic keratoses. Acta Derm Venereol. 2021;101: adv00358.","journal-title":"Acta Derm Venereol"},{"key":"1336_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/jdv.19897","volume":"38","author":"L Kandolf","year":"2024","unstructured":"Kandolf L, Peris K, Malvehy J, et al. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes). J Eur Acad Dermatol Venereol. 2024;38:1024\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.14852","volume":"177","author":"JA Siegel","year":"2017","unstructured":"Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177:350\u20138.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14092","volume":"31","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):8\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1336_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jdv.12848","volume":"29","author":"MT Fernandez-Figueras","year":"2015","unstructured":"Fernandez-Figueras MT, Carrato C, Saenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"1829884","DOI":"10.1080\/20016689.2020.1829884","volume":"8","author":"K Ezzedine","year":"2020","unstructured":"Ezzedine K, Painchault C, Brignone M. Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome. J Mark Access Health Policy. 2020;8:1829884.","journal-title":"J Mark Access Health Policy"},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13555-021-00668-9","volume":"12","author":"E Stockfleth","year":"2022","unstructured":"Stockfleth E, B\u00e9geault N, Delarue A. Intensity of local skin reactions during 5-fluorouracil treatment related to the number of actinic keratosis lesions: a post hoc, exploratory analysis. Dermatol Ther (Heidelb). 2022;12:467\u201379.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1336_CR14","first-page":"275","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18:275\u201394.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1336_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/09546634.2019.1682504","volume":"32","author":"C Navarrete-Dechent","year":"2021","unstructured":"Navarrete-Dechent C, Marghoob AA, Marchetti MA. Contemporary management of actinic keratosis. J Dermatolog Treat. 2021;32:572\u20134.","journal-title":"J Dermatolog Treat"},{"key":"1336_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jval.2015.11.014","volume":"19","author":"CV Asche","year":"2016","unstructured":"Asche CV, Zografos P, Norlin JM, et al. Evaluation of resource utilization and treatment patterns in patients with actinic keratosis in the United States. Value Health. 2016;19:239\u201348.","journal-title":"Value Health"},{"key":"1336_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels J, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935\u201346.","journal-title":"N Engl J Med"},{"key":"1336_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1001\/jamadermatol.2016.6251","volume":"153","author":"M Storer","year":"2017","unstructured":"Storer M, Zhu Z, Sokil M, Ford M, Neugebauer R, Asgari MM. Community-based practice variations in topical treatment of actinic keratoses. JAMA Dermatol. 2017;153:468\u201370.","journal-title":"JAMA Dermatol"},{"key":"1336_CR19","unstructured":"Electronic Medicines Compendium. Tolak 40 mg\/g cream. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/15802\/smpc#gref. Accessed Aug 05, 2024."},{"key":"1336_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13555-014-0059-9","volume":"4","author":"R Rosen","year":"2014","unstructured":"Rosen R, Marmur E, Anderson L, Welburn P, Katsamas J. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;4:207\u201319.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1336_CR21","unstructured":"US Food and Drug Administration. Tolak (fluorouracil) cream, 4%, for topical use. Prescribing information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022259s000lbl.pdf Accessed May 13, 2022."},{"key":"1336_CR22","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.11954","volume":"103","author":"E Stockfleth","year":"2023","unstructured":"Stockfleth E, Heppt MV, B\u00e9geault N, Delarue A. Evaluating the efficacy and safety of 4% 5-fluorouracil cream in patients with actinic keratosis: an expert opinion. Acta Derm Venereol. 2023;103: adv11954.","journal-title":"Acta Derm Venereol"},{"key":"1336_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12822","volume":"32","author":"Y Wu","year":"2019","unstructured":"Wu Y, Tang N, Cai L, Li Q. Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis. Dermatol Ther. 2019;32: e12822.","journal-title":"Dermatol Ther"},{"key":"1336_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2021.2779","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb T, Wessely A, Petzold A, et al. Evaluation of long-term clearance rates of interventions for actinic keratosis: a systematic review and network meta-analysis. JAMA Dermatol. 2021;157:1066\u201377.","journal-title":"JAMA Dermatol"},{"key":"1336_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16475","author":"AK Gupta","year":"2024","unstructured":"Gupta AK, Bamimore MA, Wang T, et al. Comparison of therapeutic agents\u2019 short-term effects on facial and scalp actinic keratosis: a network meta-analysis. J Cosmet Dermatol. 2024. https:\/\/doi.org\/10.1111\/jocd.16475.","journal-title":"J Cosmet Dermatol"},{"key":"1336_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","volume":"158","author":"S Ahmady","year":"2022","unstructured":"Ahmady S, Jansen MHE, Nelemans PJ, et al. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2022;158:634\u201340.","journal-title":"JAMA Dermatol"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","volume":"154","author":"MA Weinstock","year":"2018","unstructured":"Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. JAMA Dermatol. 2018;154:167\u201374.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01336-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:44Z","timestamp":1739837444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01336-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01336-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Markus V. Heppt has received honoraria from MSD, BMS, Roche, Novartis, Sun Pharma, Sanofi, Almirall, Biofrontera, Galderma, Immuncore, Pierre Fabre and InfectoPharm. Kilian Trin, and Alain Delarue worked in Pierre Fabre Laboratories at the time of the study. M\u00e9lanie Groc and Nathalie B\u00e9geault are employees of Pierre Fabre. Anne-C\u00e9cile Mille is an employee of Atlanstat.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This pooled analysis was based on previously conducted studies and does not contain any direct investigation with human participants or animals performed by any of the authors. Studies HD-FUP3B-048 and HD-FUP3B-049 received ethical approval from the institutional review boards of all relevant study sites and were conducted in compliance with US Food and Drug Administration regulations, the ethical principles of the Declaration of Helsinki, and the current International Conference on Harmonisation Good Clinical Practice guidelines. Patients provided written informed consent to participate in the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}